Evogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022

Rhea-AI Summary

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Jefferies Virtual Synthetic Biology Week from March 21-25, 2022. Chief Product Officer, Dr. Nir Arbel, will engage in a fireside chat on March 23, 2022, at 10 am ET and will be available for one-on-one meetings with investors on March 24, 2022. Evogene aims to transform life-science product development through its innovative technological engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbiome therapeutics, medical cannabis, ag-chemicals, and ag-biologicals.

 

REHOVOT, Israel, March 14, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the Jefferies Virtual Synthetic Biology Week which is taking place between March 21-25, 2022.

Evogene's Chief Product Officer, Dr. Nir Arbel, will participate in a fireside chat at 10am ET on Wednesday, March 23, 2022. Dr. Arbel, will also be available for one-on-one virtual meetings with investors on Thursday, March 24, 2022.

Investors that wish to meet with Dr. Arbel, are welcome to coordinate the meeting via their Jefferies representatives. Alternatively, investors may also contact Evogene's investor relations team which will coordinate a meeting.

 

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines - MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by AgPlenus and ag-biologicals by Lavie Bio Ltd.  For more information, please visit: www.evogene.com.

 

Investor Relations Contact:

Kenny Green GK Investor Relations E: evogene@gkir.com T: +1 212 378 8040

 

 

 Logo - https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg

 

 

 

View original content:https://www.prnewswire.com/news-releases/evogene-to-present-at-the-jefferies-virtual-synthetic-biology-week-on-march-23-2022-301501740.html

SOURCE Evogene

FAQ

When is Evogene's participation in the Jefferies Virtual Synthetic Biology Week?

Evogene will participate in the Jefferies Virtual Synthetic Biology Week from March 21-25, 2022.

What date will Evogene's Chief Product Officer speak at the event?

Dr. Nir Arbel, Evogene's Chief Product Officer, will speak on March 23, 2022, at 10 am ET.

How can investors meet with Dr. Nir Arbel during the event?

Investors can coordinate meetings with Dr. Arbel through their Jefferies representatives or Evogene's investor relations team.

What are the core technologies used by Evogene?

Evogene uses MicroBoost AI, ChemPass AI, and GeneRator AI for product development in life sciences.

What sectors does Evogene focus on for product development?

Evogene focuses on human microbiome therapeutics, medical cannabis products, ag-chemicals, and ag-biologicals.